CR20170285A - Compuestos de triazolopirimidina y usos de los mismos - Google Patents

Compuestos de triazolopirimidina y usos de los mismos

Info

Publication number
CR20170285A
CR20170285A CR20170285A CR20170285A CR20170285A CR 20170285 A CR20170285 A CR 20170285A CR 20170285 A CR20170285 A CR 20170285A CR 20170285 A CR20170285 A CR 20170285A CR 20170285 A CR20170285 A CR 20170285A
Authority
CR
Costa Rica
Prior art keywords
triazolopirimidine
compounds
same
prc2
disease
Prior art date
Application number
CR20170285A
Other languages
English (en)
Inventor
Man Zhang
Kehao Zhao
Wei; Qi
Long Wang
Ji Yue Zhang (Jeff);
Xiang-Ju Justin Gu
Hailong Zhang
Ho Man Chan
Ling; Li
Martin Sendzik
Qiong Zhang
Yongfeng Sun
Ying; Huang
Yuan Mi
Zhengtian Yu
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of CR20170285A publication Critical patent/CR20170285A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/541—Non-condensed thiazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems

Abstract

Se proporciona un compuesto de la Fórmula (I), o una sal farmacéuticamente aceptable del mismo, el cual se ha mostrado es útil para tratar una enfermedad o trastorno mediado por PRC2 : en donde R1, R2, R3, R4, R5, y n son como se definen en la presente.
CR20170285A 2014-12-23 2015-12-21 Compuestos de triazolopirimidina y usos de los mismos CR20170285A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN2014094644 2014-12-23
CN2015095320 2015-11-23
PCT/IB2015/059843 WO2016103155A1 (en) 2014-12-23 2015-12-21 Triazolopyrimidine compounds and uses thereof

Publications (1)

Publication Number Publication Date
CR20170285A true CR20170285A (es) 2017-08-21

Family

ID=55071101

Family Applications (1)

Application Number Title Priority Date Filing Date
CR20170285A CR20170285A (es) 2014-12-23 2015-12-21 Compuestos de triazolopirimidina y usos de los mismos

Country Status (39)

Country Link
US (5) US9580437B2 (es)
EP (1) EP3237418B1 (es)
JP (1) JP6736559B2 (es)
KR (1) KR102534028B1 (es)
CN (1) CN107108637B (es)
AU (1) AU2015370524B2 (es)
BR (1) BR112017010354B8 (es)
CA (1) CA2969090C (es)
CL (1) CL2017001572A1 (es)
CO (1) CO2017005992A2 (es)
CR (1) CR20170285A (es)
CY (1) CY1121901T1 (es)
DK (1) DK3237418T3 (es)
DO (1) DOP2017000149A (es)
EA (1) EA032416B1 (es)
EC (1) ECSP17047153A (es)
ES (1) ES2722048T3 (es)
GT (1) GT201700146A (es)
HR (1) HRP20190805T1 (es)
HU (1) HUE043060T2 (es)
IL (1) IL252135B (es)
JO (1) JO3489B1 (es)
LT (1) LT3237418T (es)
ME (1) ME03385B (es)
MX (1) MX2017008529A (es)
MY (1) MY186837A (es)
PE (1) PE20171307A1 (es)
PH (1) PH12017501016A1 (es)
PL (1) PL3237418T3 (es)
PT (1) PT3237418T (es)
RS (1) RS58679B1 (es)
SG (1) SG11201703880VA (es)
SI (1) SI3237418T1 (es)
SV (1) SV2017005472A (es)
TN (1) TN2017000204A1 (es)
TW (1) TWI694076B (es)
UA (1) UA120945C2 (es)
UY (1) UY36462A (es)
WO (1) WO2016103155A1 (es)

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUE043060T2 (hu) * 2014-12-23 2019-07-29 Novartis Ag Triazolopirimidin-vegyületek és alkalmazásaik
JP7121660B2 (ja) * 2016-06-01 2022-08-18 エピザイム，インコーポレイティド 癌を処置するためのｅｚｈ２阻害剤の使用
EP3472168B1 (en) * 2016-06-20 2024-01-10 Novartis AG Crystalline forms of triazolopyrimidine compound
WO2017221092A1 (en) * 2016-06-20 2017-12-28 Novartis Ag Triazolopyridine compounds and uses thereof
CN109790166A (zh) * 2016-06-20 2019-05-21 诺华股份有限公司 咪唑并吡啶化合物用于治疗癌症
WO2018013597A1 (en) 2016-07-12 2018-01-18 Revolution Medicines, Inc. 2,5-disubstituted 3-methyl pyrazines and 2,5,6-trisubstituted 3-methyl pyrazines as allosteric shp2 inhibitors
CN106831601A (zh) * 2017-01-13 2017-06-13 河北博伦特药业有限公司 一种2‑氨基甲基嘧啶盐酸盐及其衍生物的合成方法
BR112019014527A2 (pt) 2017-01-23 2020-02-27 Revolution Medicines, Inc. Compostos de piridina como inibidores de shp2 alostéricos
BR112019015075A2 (pt) 2017-01-23 2020-03-10 Revolution Medicines, Inc. Compostos bicíclicos como inibidores de shp2 alostéricos
US10266542B2 (en) 2017-03-15 2019-04-23 Mirati Therapeutics, Inc. EZH2 inhibitors
WO2018170290A1 (en) * 2017-03-15 2018-09-20 Fulcrum Therapeutics, Inc. Compositions and methods for increasing fmr1 expression
CA3054976A1 (en) * 2017-03-16 2018-09-20 Jiangsu Hengrui Medicine Co., Ltd. Heteroaryl[4,3-c]pyrimidine-5-amine derivative, preparation method therefor, and medical uses thereof
US11602529B2 (en) 2017-06-02 2023-03-14 Epizyme, Inc. Use of EZH2 inhibitors for treating cancer
WO2019062435A1 (zh) * 2017-09-28 2019-04-04 中国科学院上海药物研究所 三氮唑并嘧啶、三氮唑并吡啶化合物及其组合物用于治疗prc2介导的疾病
CN109575013A (zh) * 2017-09-28 2019-04-05 中国科学院上海药物研究所 三氮唑并嘧啶、三氮唑并吡啶化合物及其组合物用于治疗prc2介导的疾病
RU2020115095A (ru) 2017-10-12 2021-11-12 Революшн Медсинз, Инк. Пиридиновые, пиразиновые и триазиновые соединения в качестве аллостерических ингибиторов shp2
CN109867645B (zh) * 2017-12-05 2021-09-14 中国医学科学院药物研究所 一种2,2-二氟-2,3-二氢取代苯并呋喃类化合物的合成方法
CN111433205B (zh) 2017-12-15 2024-01-19 锐新医药公司 作为变构shp2抑制剂的多环化合物
CN109942556A (zh) * 2017-12-21 2019-06-28 上海青煜医药科技有限公司 嘧啶酮化合物及其应用
EP3743416B1 (en) 2018-01-23 2023-03-15 Basf Se Halogenation of pyridine derivatives
JP7025556B2 (ja) * 2018-01-31 2022-02-24 ミラティ セラピューティクス， インコーポレイテッド Ｐｒｃ２阻害剤
CN110156787B (zh) * 2018-02-13 2021-11-02 中国科学院上海药物研究所 一种三氮唑并嘧啶衍生化合物、包含其的药物组合物及其用途
CN110563722A (zh) * 2018-06-06 2019-12-13 上海青煜医药科技有限公司 吡啶或哒嗪并环化合物及其应用
CN110734436A (zh) * 2018-07-19 2020-01-31 上海青煜医药科技有限公司 嘧啶或吡嗪并环化合物及其应用
CA3120791A1 (en) * 2018-11-30 2020-06-04 Tuojie Biotech (Shanghai) Co., Ltd. Pyrimidine and five-membered nitrogen heterocycle derivative, preparation method therefor, and medical uses thereof
CN111518100A (zh) * 2019-02-02 2020-08-11 上海青煜医药科技有限公司 环丙烯并苯并呋喃取代的氮杂芳基化合物及其应用
WO2020204024A1 (ja) * 2019-04-03 2020-10-08 テラ・ストーン株式会社 チミン核酸塩基をベースとするトリアゾロピリミジン類及びその製造方法
WO2020219448A1 (en) * 2019-04-22 2020-10-29 Mirati Therapeutics, Inc. Naphthyridine derivatives as prc2 inhibitors
CN113874377A (zh) 2019-05-13 2021-12-31 埃科莱布美国股份有限公司 作为铜腐蚀抑制剂的1,2,4-***并[1,5-a]嘧啶衍生物
CA3142477A1 (en) * 2019-06-05 2020-12-10 Athenex, Inc. Methods of treating and/or preventing psoriasis
WO2020247475A1 (en) * 2019-06-05 2020-12-10 Mirati Therapeutics, Inc. Imidazo[1,2-c]pyrimidine derivatives as prc2 inhibitors for treating cancer
CN112409385A (zh) * 2019-08-22 2021-02-26 上海青煜医药科技有限公司 氮杂芳基化合物及其应用
KR20220070229A (ko) * 2019-09-26 2022-05-30 노파르티스 아게 아자-퀴놀린 화합물 및 그의 용도
CA3156546A1 (en) * 2019-11-01 2021-05-06 Wei Qi Substituted [1,2,4]triazolo-[4,3-c]pyrimidine compounds and use thereof as eed inhibitors
CN113004233B (zh) * 2019-12-18 2022-12-20 南京优氟医药科技有限公司 一种用于制备prc2抑制剂的化合物、其制备方法和用途
CN111333655B (zh) * 2020-04-13 2021-07-13 武汉工程大学 一种***并嘧啶类化合物及其制备方法和应用
US20220298129A1 (en) * 2020-05-11 2022-09-22 Ascentage Pharma (Suzhou) Co., Ltd. Preparation method of (5-fluoro-2,3-dihydrobenzofuran-4-yl)methanamine or its salt, and intermediates thereof
CN115916209A (zh) 2020-05-28 2023-04-04 诺华股份有限公司 用于治疗PRC2介导的疾病或障碍的N-((5-氟-2,3-二氢苯并呋喃-4-基)甲基)-8-(2-甲基吡啶-3-基)-[1,2,4]***并[4,3-c]嘧啶-5-胺或其药学上可接受的盐的给药方案
CN114907385A (zh) 2021-02-10 2022-08-16 上海青煜医药科技有限公司 氮杂芳基化合物、其制备方法及应用
CN115703799A (zh) * 2021-08-11 2023-02-17 上海青煜医药科技有限公司 氮杂芳基化合物、其制备方法及应用
CN117384153A (zh) * 2022-07-12 2024-01-12 上海赛岚生物科技有限公司 一类甲基转移酶抑制剂及其用途

Family Cites Families (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2779780A (en) 1955-03-01 1957-01-29 Du Pont 1, 4-diamino-2, 3-dicyano-1, 4-bis (substituted mercapto) butadienes and their preparation
EP0647450A1 (en) 1993-09-09 1995-04-12 BEHRINGWERKE Aktiengesellschaft Improved prodrugs for enzyme mediated activation
HUP0104693A3 (en) 1998-12-16 2003-12-29 Warner Lambert Co Treatment of arthritis with mek inhibitors
NL1014106C2 (nl) 2000-01-18 2001-07-20 Univ Amsterdam Werkwijze voor het detecteren van een pathologische afwijking bij een cel, een antistof en een assay kit.
EE05450B1 (et) 2000-07-19 2011-08-15 Warner-Lambert Company 4-jodofenlaminobenshdroksaamhapete oksgeenitud estrid, nende kristallvormid ja farmatseutilised kompositsioonid ning kasutamine
SE519662C2 (sv) * 2001-07-04 2003-03-25 Asept Int Ab Ventilanordning vid utportioneringsanordningar
WO2003034997A2 (en) * 2001-10-24 2003-05-01 Iconix Pharmaceuticals, Inc. Modulators of phosphoinositide 3-kinase
US6921762B2 (en) * 2001-11-16 2005-07-26 Amgen Inc. Substituted indolizine-like compounds and methods of use
PL221491B1 (pl) 2002-03-08 2016-04-29 Eisai R&D Man Co Związki makrocykliczne, środek farmaceutyczny zawierający te związki oraz zastosowanie tych związków
PL401637A1 (pl) 2002-03-13 2013-05-27 Array Biopharma Inc. N3 alkilowane pochodne benzimidazolu jako inhibitory MEK
GB0228900D0 (en) 2002-12-11 2003-01-15 Ml Lab Plc Cancer Immunotherapy
JP2004238296A (ja) * 2003-02-04 2004-08-26 Kissei Pharmaceut Co Ltd 新規なトリアゾロピリミジン誘導体、それを含有する医薬組成物およびそれらの用途
CA2514733A1 (en) 2003-02-28 2004-09-16 Transform Pharmaceuticals, Inc. Pharmaceutical co-crystal compositions of drugs such as carbamazepine, celecoxib, olanzapine, itraconazole, topiramate, modafinil, 5-fluorouracil, hydrochlorothiazide, acetaminophen, aspirin, flurbiprofen, phenytoin and ibuprofen
CA2528669A1 (en) 2003-06-09 2005-01-20 The Regents Of The University Of Michigan Compositions and methods for treating and diagnosing cancer
US20060246505A1 (en) 2003-09-02 2006-11-02 Reinhard Walther Modulation of the synthesis of insulin
EP1765994B1 (en) 2004-06-01 2009-11-18 The University of North Carolina at Chapel Hill Reconstituted histone methyltransferase complex and methods of identifying modulators thereof
GB0510390D0 (en) 2005-05-20 2005-06-29 Novartis Ag Organic compounds
US7452892B2 (en) 2005-06-17 2008-11-18 Bristol-Myers Squibb Company Triazolopyrimidine cannabinoid receptor 1 antagonists
CA2618218C (en) 2005-07-21 2015-06-30 Ardea Biosciences, Inc. N-(arylamino)-sulfonamide inhibitors of mek
JO2660B1 (en) 2006-01-20 2012-06-17 نوفارتيس ايه جي Pi-3 inhibitors and methods of use
US7890267B2 (en) 2006-03-31 2011-02-15 Ordway Research Institute Prognostic and diagnostic method for cancer therapy
WO2008083251A2 (en) 2006-12-27 2008-07-10 Usc Stevens - University Of Southern California Dna methylation markers based on epigenetic stem cell signatures in cancer
WO2009017670A2 (en) 2007-07-26 2009-02-05 University Of Massachusetts Ras-mediated epigenetic silencing effectors and uses thereof
WO2009026720A1 (en) 2007-08-29 2009-03-05 Methylgene Inc. Processes and intermediates for preparing fused heterocyclic kinase inhibitors
KR101584823B1 (ko) 2007-09-12 2016-01-22 제넨테크, 인크. 포스포이노시타이드 3-키나제 저해제 화합물과 화학치료제의 배합물 및 이의 사용방법
US8354528B2 (en) 2007-10-25 2013-01-15 Genentech, Inc. Process for making thienopyrimidine compounds
US8168784B2 (en) 2008-06-20 2012-05-01 Abbott Laboratories Processes to make apoptosis promoters
GB0822248D0 (en) 2008-12-05 2009-01-14 Medical Res Council Crystal meths
WO2010111712A2 (en) 2009-03-27 2010-09-30 Cold Spring Harbor Laboratory Identification of rnai targets and use of rnai for rational therapy of chemotherapy-resistant leukemia and other cancers
CN102020643A (zh) 2009-09-22 2011-04-20 上海恒瑞医药有限公司 二氢喋啶酮类衍生物、其制备方法及其在医药上的应用
TW201200518A (en) 2010-03-10 2012-01-01 Kalypsys Inc Heterocyclic inhibitors of histamine receptors for the treatment of disease
PL2566327T3 (pl) * 2010-05-07 2017-09-29 Glaxosmithkline Llc Indole
DK2614369T3 (en) 2010-09-10 2016-05-02 Epizyme Inc METHOD FOR DETERMINING THE SUITABILITY OF HUMAN EZH2 INHIBITORS TREATED
WO2012151277A1 (en) 2011-05-02 2012-11-08 Applied Informatic Solutions, Inc. Kits and methods for selecting a treatment for ovarian cancer
WO2013010181A2 (en) 2011-07-14 2013-01-17 University Of Massachusetts Methods of diagnosing cancer using epigenetic biomarkers
CA2850570A1 (en) 2011-09-30 2013-04-04 Glaxosmithkline Llc Methods of treating cancer
WO2013138361A1 (en) 2012-03-12 2013-09-19 Epizyme, Inc. Inhibitors of human ezh2, and methods of use thereof
CN105189506A (zh) 2012-11-19 2015-12-23 诺华股份有限公司 用于治疗寄生虫疾病的化合物和组合物
US20150313906A1 (en) 2012-12-19 2015-11-05 Glaxosmithkline Llc Combination
CA2900764A1 (en) 2013-02-08 2014-08-14 Stemcentrx, Inc. Novel multispecific constructs
PE20160044A1 (es) 2013-02-11 2016-02-11 Constellation Pharmaceuticals Inc Moduladores de las enzimas modificadoras de los metilos, composiciones que los comprenden y sus usos
RU2015139054A (ru) 2013-03-14 2017-04-19 Дженентек, Инк. Способы лечения рака и профилактики лекарственной резистентности рака
EP2970306A4 (en) 2013-03-15 2016-08-03 Epizyme Inc SUBSTITUTED BICYCLIC HETEROARYL COMPOUNDS CONDENSED IN 6.5
US9745305B2 (en) 2013-03-15 2017-08-29 Constellation Pharmaceuticals, Inc. Modulators of methyl modifying enzymes, compositions and uses thereof
HRP20220759T1 (hr) 2014-02-11 2022-09-02 Mitokinin, Inc. Pripravci i postupci koji ih koriste za liječenje neurodegenerativne i mitohondrijske bolesti
RU2731051C2 (ru) 2014-11-14 2020-08-28 Басф Се Бензилпропаргиловые простые эфиры в качестве ингибиторов нитрификации
SI3033944T1 (en) 2014-12-16 2018-06-29 Omya International Ag Calcium carbonate for plant protection
GB201501017D0 (en) 2014-12-23 2015-03-04 Immatics Biotechnologies Gmbh Novel peptides and combination of peptides for use in immunotherapy against hepatocellular carcinoma (HCC) and other cancers
HUE043060T2 (hu) * 2014-12-23 2019-07-29 Novartis Ag Triazolopirimidin-vegyületek és alkalmazásaik
MA41272A (fr) 2014-12-23 2017-10-31 Adama Makhteshim Ltd 5-fluoro-4-imino-3-(alkyle/alkyle substitué)-1-(arylsulfonyl)-3,4-dihydropyrimidin-2(1h)-one en tant que traitement des semences

Also Published As

Publication number Publication date
US11207325B2 (en) 2021-12-28
IL252135A0 (en) 2017-07-31
LT3237418T (lt) 2019-05-10
CY1121901T1 (el) 2020-10-14
IL252135B (en) 2020-06-30
BR112017010354A2 (pt) 2017-12-26
EA201791420A1 (ru) 2017-10-31
US20160176882A1 (en) 2016-06-23
UY36462A (es) 2016-07-29
TN2017000204A1 (en) 2018-10-19
EA032416B1 (ru) 2019-05-31
US9580437B2 (en) 2017-02-28
AU2015370524B2 (en) 2018-11-01
AU2015370524A1 (en) 2017-06-01
ECSP17047153A (es) 2019-02-28
UA120945C2 (uk) 2020-03-10
HUE043060T2 (hu) 2019-07-29
JO3489B1 (ar) 2020-07-05
WO2016103155A1 (en) 2016-06-30
PT3237418T (pt) 2019-05-23
EP3237418A1 (en) 2017-11-01
PH12017501016B1 (en) 2017-12-11
PL3237418T3 (pl) 2019-07-31
CL2017001572A1 (es) 2018-01-12
ME03385B (me) 2020-01-20
ES2722048T3 (es) 2019-08-07
KR20170095882A (ko) 2017-08-23
HRP20190805T1 (hr) 2019-06-28
US11931363B2 (en) 2024-03-19
MX2017008529A (es) 2017-10-25
CA2969090C (en) 2023-05-02
EP3237418B1 (en) 2019-01-30
US20200323859A1 (en) 2020-10-15
PE20171307A1 (es) 2017-09-05
US10220036B2 (en) 2019-03-05
KR102534028B1 (ko) 2023-05-19
MY186837A (en) 2021-08-25
US20230033320A1 (en) 2023-02-02
BR112017010354B1 (pt) 2022-09-20
CN107108637A (zh) 2017-08-29
CO2017005992A2 (es) 2017-10-20
JP6736559B2 (ja) 2020-08-05
SV2017005472A (es) 2018-06-12
DOP2017000149A (es) 2017-07-15
US20170348312A1 (en) 2017-12-07
GT201700146A (es) 2019-06-12
DK3237418T3 (da) 2019-05-13
SG11201703880VA (en) 2017-07-28
SI3237418T1 (sl) 2019-06-28
BR112017010354B8 (pt) 2022-10-18
TWI694076B (zh) 2020-05-21
US20190142837A1 (en) 2019-05-16
CA2969090A1 (en) 2016-06-30
JP2018500342A (ja) 2018-01-11
RS58679B1 (sr) 2019-06-28
TW201629065A (zh) 2016-08-16
PH12017501016A1 (en) 2017-12-11
CN107108637B (zh) 2019-10-29

Similar Documents

Publication Publication Date Title
DOP2017000149A (es) Compuestos de triazolopirimidina y usos de los mismos
CO2017001884A2 (es) Polimorfos de selinexor
CR20170237A (es) Nuevos compuestos de 5-amino-6h-tiazolo[4,5-d]pirimidin-2,7-diona 3-sustituidos para el tratamiento y profilaxis de infecciones virales.
CU24411B1 (es) Compuesto derivado de benzamida sustituida con 1,3-tiazol-2-ilo útil para el tratamiento de trastornos neurogénicos
CO2018000589A2 (es) Oxiesteroles y composiciones farmacéuticas que los contienen
CL2019000844A1 (es) Compuesto de piridina.
CO2019000932A2 (es) Nuevos compuestos sulfonimidoilpurinona 7-sustituidos y derivados para el tratamiento y la profilaxis de la infección vírica.
CU24605B1 (es) Pirimidin-2-il amino-1h-pirazoles útiles como inhibidores de lrrk2
DOP2015000201A (es) Compuestos de azabencimidazol como inhibidores de pde4 isoenzimas para el tratamiento del snc y otros trastornos
UY37774A (es) Compuestos 5-cianoindol sustituidos y usos de los mismos
CR20150078A (es) Análogos de piridazina 1,4-disustituida y métodos para el tratamiento de condiciones relacionadas con la deficiencia de smn
CU20160192A7 (es) Derivados de indano e indolina útiles como activadores de la guanilato ciclasa soluble
DOP2017000034A (es) Compuestos de imidazopiridazina
CU20160003A7 (es) Pirazololpiridinaminas sustituidas
AR095097A1 (es) Compuestos de fenoxietoxi
ECSP18003372A (es) Compuestos tricíclicos y su uso como inhibidores de la fosfodiesterasa
CL2019000487A1 (es) Derivado de triazolopirazinona útil como un inhibidor de pde1 humana.
AR098134A1 (es) Compuestos de urea
GT201500232A (es) Compuestos de azabencimidazol como inhibidores de las isozimas pde4 para el tratamiento de cns y otros trastornos